J&J Calls Actelion Tender Offer Successful

(c) J&J
(c) J&J

Based on interim results of its $280 per share tender offer for all publicly held shares of Swiss  biopharmaceuticals company Actelion, US healthcare giant Johnson & Johnson has declared the offer carried out through its Swiss subsidiary Janssen Holding a success.

The main offer period ended on Mar. 30, with 73.25% of the 107,339,642 shares covered by the offer tendered. Altogether, shares corresponding to 77.20% of the voting rights and the share capital of Actelion are now held by New Jersey-based J&J. The additional acceptance period of ten trading days on the Swiss stock exchange SIX will begin on Ap. 6 and expire on April 21, the company said.

J&J has announced also that the applicable waiting periods under the amended Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the proposed acquisition have either expired or been terminated early. The Japan Fair Trade Commission and the Israeli Antitrust Authority have already cleared the deal, which is expected to close in the second quarter following all approvals. A prerequisite for the acquisition to go ahead was that 67% of share capital agreed to tender.

Previously announced terms call for Actelion to spin off its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical firm called Idorsia and headed by Actelion founder Jean-Pierre Garnier as CEO. Shares in Idorsia are to be distributed to Actelion's shareholders as a dividend. J&J will initially take a minority stake of 16% in the research spinoff, with the right to acquire an additional 16% later, through a convertible note.

The US company is said to be paying more than 21 times Actelion’s estimated 2020 per-share earnings, which has led some analysts to declare the takeover too expensive. The transaction is taking place under the shadow of a proposal by the new US administration to rewrite the US tax code to induce American companies to repatriate untaxed offshore funds at reduced rates. Earlier reports suggested that J&J may hold as much as $42 billion in cash overseas.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.